Research in Context is a structured summary that editors at The Lancet’s journals ask all authors to provide when submitting an original research article. Read more
Stay at the forefront of renal cell carcinoma and kidney cancer care with insights from the Lancet, featuring groundbreaking research and authoritative reviews that inform the latest advances in diagnosis, treatment, and patient care.
Investigators reported no local progression during the study period and said the findings justify a randomised trial of surgery versus SABR.
The Lancet Group reaches millions of clinicians and researchers worldwide.
A non-randomised, pooled analysis of two prospective trials reports 5-year local control, cancer-specific survival, adverse-event, and renal-function outcomes after ultra-hypofractionated SABR in patients who were inoperable, high risk or unsuitable for surgery, or declined surgery.
Investigators reported prolonged deferral of systemic therapy and exploratory prognostic factors, including ctDNA, in this phase 2 trial.
In the ongoing phase 2 LITESPARK-004 study, nearly 50 months of follow-up showed durable responses and a continued low need for surgical intervention in participants with VHL disease-associated lesions.
Exploratory secondary analyses from LITESPARK-005 suggested maintenance or improvement in PRO scores with belzutifan versus everolimus.
According to the authors, randomised trials are still needed to confirm long-term outcomes; a new large-scale meta-analysis suggests SBRT might be advantageous for larger tumours, with comparatively low rates of severe complications.
Investigators reported no efficacy for PD-1 rechallenge with tivozanib plus nivolumab after progression on previous ICI combination therapy, while the authors noted clinical activity for full-dose tivozanib monotherapy in this setting.
Researchers report high diagnostic performance for the investigational agent Zr-89-girentuximab PET–CT in identifying clear-cell renal cell carcinoma, with further trials warranted to assess patient-management effects and clinical utility in other renal cancer subtypes.
Investigators reported no local treatment failures during the study period, with the authors saying the results support a future randomised trial of surgery versus SABR.
A retrospective multicentre validation study reports that a histopathological, genomic, and clinical scoring system predicted recurrence risk after surgery more accurately than TNM staging and established single-modality systems in independent Chinese cohorts and TCGA data.